Quinupristin/Dalfopristin

Class: Streptogramins
- Synergistin Antibiotics
VA Class: AM900
Chemical Name: (S)-4-[4-(Dimethylamino)-N-methyl-l-phenylalanine]-5-[5-[(1-azabicyclo[2.2.2]oct-3-ylthio)methyl]-4-oxo-l-2-piperidinecarboxylic acid]-virginiamycin
Molecular Formula: C₅₃H₆₇N₉O₁₀SC₃₄H₅₀N₄O₉S
CAS Number: 120138-50-3

Medically reviewed by Drugs.com on May 23, 2022. Written by ASHP.

Introduction

Antibacterial; fixed combination of quinupristin and dalfopristin, 2 semisynthetic streptogramin antibiotics that act synergistically against susceptible bacteria.

Uses for Quinupristin/Dalfopristin

Skin and Skin Structure Infections

Treatment of complicated skin and skin structure infections caused by susceptible Staphylococcus aureus (methicillin-susceptible [oxacillin-susceptible] strains) or Streptococcus pyogenes (group A β-hemolytic streptococci, GAS).

For information on diagnosis and management of skin and skin structure infections, consult current IDSA clinical practice guidelines available at [Web].

Methicillin-resistant Staphylococcus aureus Infections

Has been used as salvage therapy in critically ill patients for treatment of severe infections (e.g., bacteremia, infective endocarditis) caused by methicillin-resistant S. aureus† (MRSA; also known as oxacillin-resistant S. aureus or ORSA) when vancomycin was ineffective.

Some clinicians state quinupristin/dalfopristin is one of several options for treatment of persistent MRSA bacteremia in adults who fail to respond to vancomycin or when the infection is known to be caused by MRSA with reduced susceptibility to vancomycin and daptomycin.

For information on treatment of infections caused by MRSA, consult current IDSA clinical practice guidelines available at [Web]. For information on diagnosis and management of infective endocarditis caused by MRSA, consult current AHA guidelines available at [Web].

Vancomycin-resistant Enterococcus faecium Infections

Has been used for treatment of serious or life-threatening infections caused by susceptible vancomycin-resistant Enterococcus faecium†, including bacteremia, infective endocarditis, intra-abdominal infections, skin and skin structure infections, and urinary tract infections.

Treatment of vancomycin-resistant E. faecium infections no longer included in FDA-approved labeling; some clinicians suggest reserving quinupristin/dalfopristin for refractory vancomycin-resistant E. faecium infections that fail to respond to other anti-infectives.

Quinupristin/Dalfopristin Dosage and Administration

Administration

Administer by IV infusion over 60 minutes.

IV Infusion

For solution and drug compatibility, see Compatibility under Stability.

Do not administer by rapid IV infusion or injecti..